BMJ Best Practice

参考文献

关键文献

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.

World Health Organization. International classification of diseases: 10th revision, second edition. Geneva, Switzerland: World Health Organization; 2004.

Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.

Wolraich M, Brown L, Brown RT, et al; Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007-1022.

参考文章

1.  American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.

2.  World Health Organization. International classification of diseases: 10th revision, second edition. Geneva, Switzerland: World Health Organization; 2004.

3.  Schonwald A, Lechner E. Attention deficit/hyperactivity disorder: complexities and controversies. Curr Opin Pediatr. 2006;18:189-195.

4.  Barkley RA. Attention deficit hyperactivity disorder: a clinical handbook, 3rd ed. New York: Guilford; 2005.

5.  Faraone SV, Biederman J, Jetton JG, et al. Attention deficit disorder and conduct disorder: longitudinal evidence for a familial subtype. Psychol Med. 1997;27:291-300.

6.  Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1997;36:21-29.

7.  Milberger S, Biederman J, Faraone SV, et al. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997;36:37-44.

8.  Faraone SV, Biederman J. Do attention deficit hyperactivity disorder and major depression share familial risk factors? J Nerv Ment Dis. 1997;185:533-541.

9.  Biederman J, Faraone S, Mick E, et al. Attention-deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Psychiatry. 1996;35:997-1008.

10.  Spencer TJ, Biederman MD, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol. 2007;32:631-642.

11.  Pliszka SR, Carlson CL, Swanson JM. ADHD with comorbid disorders: clinical assessment and management. New York, NY: Guilford; 1999.

12.  Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942-948.

13.  Centers for Disease Control and Prevention. Key findings: trends in the parent-report of health care provider-diagnosis and medication treatment for ADHD: United States, 2003-2011. February 2017. http://www.cdc.gov/ (last accessed 7 August 2017).

14.  Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2010. Vital Health Stat 10. 2011;250:1-80.

15.  Biederman J, Faraone SV. The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives. Psychiatr Clin North Am. 2004;27:225-232.

16.  Cuffe SP, Moore CG, McKeown RE. Prevalence and correlates of ADHD symptoms in the National Health Interview Survey. J Atten Disord. 2005;9:392-401.

17.  Epstein JN, Willoughby M, Valencia EY, et al. The role of children's ethnicity in the relationship between teacher ratings of attention-deficit/hyperactivity disorder and observed classroom behavior. J Consult Clin Psychol. 2005;73:424-434.

18.  Langley K, Holmans PA, van den Bree MB, Thapar A. Effects of low birth weight, maternal smoking in pregnancy and social class on the phenotypic manifestation of attention deficit hyperactivity disorder and associated antisocial behavior: investigation in a clinical sample. BMC Psychiatry. 2007;7:26.

19.  Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1313-1323.

20.  Waldman ID, Gizer IR. The genetics of attention deficit hyperactivity disorder. Clin Psychol Rev. 2006;26:396-432.

21.  Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.

22.  Thapar A, O'Donovan MC, Owen MJ. The genetics of attention deficit hyperactivity disorder. Hum Mol Genet. 2005;14:R275-R282.

23.  Lahat E, Heyman E, Livne A, et al. Iron deficiency in children with attention deficit hyperactivity disorder. Isr Med Assoc J. 2011;13:530-533.

24.  Froehlich TE, Anixt JS, Loe IM, et al. Update on environmental risk factors for attention-deficit/hyperactivity disorder. Curr Psychiatry Rep. 2011;13:333-344.

25.  Man KK, Chan EW, Ip P, et al. Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. BMJ. 2017;357:j2350.

26.  Greenhill LL. Stimulant medication treatment of children with attention deficit hyperactivity disorder. In: Jensen PS, Cooper JR, eds. Attention deficit hyperactivity disorder: state of science. best practices. Kingston, NH: Civic Research Institute 2002:9-1-9-27.

27.  Wilens TE. Mechanism of action of agents used in attention deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67:32-38.

28.  Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1397-1409.

29.  Sengupta SM, Grizenko N, Thakur GA, et al. Differential association between the norepinephrine transporter gene and ADHD: role of sex and subtype. J Psychiatry Neurosci. 2012;37:129-137.

30.  Elia J, Glessner JT, Wang K, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet. 2011;44:78-84.

31.  Wargelius HL, Malmberg K, Larsson JO, et al. Associations of MAOA-VNTR or 5HTT-LPR alleles with attention-deficit hyperactivity disorder symptoms are moderated by platelet monoamine oxidase B activity. Psychiatr Genet. 2012;22:42-45.

32.  Cortese S. The neurobiology and genetics of attention-deficit/hyperactivity disorder (ADHD): what every clinician should know. Eur J Paediatr Neurol. 2012;16:422-433.

33.  Willcutt EG, Doyle AE, Nigg JT, et al. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry. 2005;57:1336-1346.

34.  Valera EM, Faraone SV, Murray KE, et al. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61:1361-1369.

35.  Duerden EG, Tannock R, Dockstader C. Altered cortical morphology in sensorimotor processing regions in adolescents and adults with attention-deficit/hyperactivity disorder. Brain Res. 2012;1445:82-91.

36.  Nakao T, Radua J, Rubia K, et al. Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. Am J Psychiatry. 2011;168:1154-1163.

37.  Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry. 2005;57:1273-1284.

38.  Mills KL, Bathula D, Dias TG, et al. Altered cortico-striatal-thalamic connectivity in relation to spatial working memory capacity in children with ADHD. Front Psychiatry. 2012;3:2.

39.  Tomasi D, Volkow ND. Abnormal functional connectivity in children with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2012;71:443-450.

40.  Cortese S, Castellanos FX. Neuroimaging of attention-deficit/hyperactivity disorder: current neuroscience-informed perspectives for clinicians. Curr Psychiatry Rep. 2012;14:568-578.

41.  Szatmari P, Saigal S, Rosenbaum P, et al. Psychiatric disorders at five years among children with birth weights less than 1000g: a regional perspective. Dev Med Child Neurol. 1990;32:954-962.

42.  Mick E, Biederman J, Prince J, et al. Impact of low birth weight on attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2002;23:16-22.

43.  Groen-Blokhuis MM, Middeldorp CM, van Beijsterveldt CE, et al. Evidence for a causal association of low birth weight and attention problems. J Am Acad Child Adolesc Psychiatry. 2011;50:1247-1254.

44.  Dunn DW, Bourgeois BFD. Learning disabilities and ADHD in children with epilepsy. In: Duchowny M, Cross JH, Arzimanoglou A, eds. Pediatric epilepsy. New York, NY: McGraw Hill Medical; 2013:323-329.

45.  Masur D, Shinnar S, Cnaan A, et al; Childhood Absence Epilepsy Study Group. Pretreatment cognitive deficits and treatment effects on attention in childhood absence epilepsy. Neurology. 2013;81:1572-1580.

46.  Rodriguez A, Bohlin G. Are maternal smoking and stress during pregnancy related to ADHD symptoms in children? J Child Psychol Psychiatry. 2005;26:246-254.

47.  Rutter M, Cox A, Tupling C, et al. Attainment and adjustment in two geographical areas. 1 - The prevalence of psychiatric disorders. Br J Psychiatry. 1975;126:493-509.

48.  Biederman J, Milberger S, Faraone SV, et al. Family-environment risk factors for attention-deficit hyperactivity disorder. A test of Rutter's indicators of adversity. Arch Gen Psychiatry. 1995;52:464-470.

49.  Biederman J, Faraone SV, Monuteaux MC. Differential effect of environmental adversity by gender: Rutter's index of adversity in a sample of boys and girls with and without ADHD. Am J Psychiatry. 2002;159:1556-1562.

50.  Braun JM, Kahn RS, Froehlich T, et al. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect. 2006;114:1904-1909.

51.  Max JE, Arndt S, Castillo CS, et al. Attention-deficit hyperactivity disorder symptomatology after traumatic brain injury: a prospective study. J Am Acad Child Adolesc Psychiatry. 1998;37:841-847.

52.  Kreppner JM, O'Connor TG, Rutter M. Can inattention/overactivity be an institutional deprivation syndrome? J Abnorm Child Psychol. 2001;29:513-528.

53.  Cortese S, Angriman M, Lecendreux M, et al. Iron and attention deficit/hyperactivity disorder: what is the empirical evidence so far? A systematic review of the literature. Expert Rev Neurother. 2012;12:1227-1240.

54.  Manor I, Magen A, Keidar D, et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. Eur Psychiatry. 2012;27:335-342.

55.  Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2011;50:991-1000.

56.  Gillies D, Sinn JKH, Lad SS, et al. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2012;(7):CD007986.

57.  Perera H, Jeewandara KC, Seneviratne S, et al. Combined omega-3 and omega-6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. J Child Neurol. 2012;27:747-753.

58.  Pineda DA, Puerta IC, Aguirre DC, et al. The role of neuropsychological tests in the diagnosis of attention deficit hyperactivity disorder. Pediatr Neurol. 2007;36:373-381.

59.  Weiler MD, Bernstein JH, Bellinger DC, et al. Processing speed in children with attention deficit/hyperactivity disorder, inattentive type. Child Neuropsychol. 2000;6:218-234.

60.  de Boo GM, Prins PJ. Social incompetence in children with ADHD: possible moderators and mediators in social-skills training. Clin Psychol Rev. 2007;27:78-97.

61.  Chang LY, Wang MY, Tsai PS. Diagnostic accuracy of rating scales for attention-deficit/hyperactivity disorder: a meta-analysis. Pediatrics. 2016;137:e20152749.

62.  Steiner H, Remsing L, Work Group on Quality Issues. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Oppositional Defiant Disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:126-141.

63.  Woolf AD, Goldman R, Bellinger DC. Update on the clinical management of childhood lead poisoning. Pediatr Clin North Am. 2007;54:271-294.

64.  Sandoval C, Jayabose S, Eden AN. Trends in diagnosis and management of iron deficiency during infancy and early childhood. Hematol Oncol Clin North Am. 2004;18:1423-1438.

65.  Wattendorf DJ, Muenke M. Fetal alcohol spectrum disorders. Am Fam Physician. 2005;72:279-282;285.

66.  Sokol RJ, Martier SS, Ager JW. The T-ACE questions: practical prenatal detection of risk-drinking. Am J Obstet Gynecol. 1989;160:863-868.

67.  Kaufman DM. Congenital cerebral impairments. In: Kaufman DM. Clinical neurology for psychiatrists. 6th ed. Bronx, NY: Elsevier; 2007:295-311.

68.  McKeown NJ, Tews MC, Gossain VV, et al. Hyperthyroidism. Emerg Med Clin North Am. 2005;23:669-685;viii.

69.  Meltzer LJ. Mindell JA. Sleep and sleep disorders in children and adolescents. Psychiatr Clin North Am. 2006;29:1059-1076.

70.  Wolraich M, Brown L, Brown RT, et al; Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007-1022.

71.  Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V: scales assessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2003;42:1015-1037.

72.  Ghuman JK, Arnold LE, Anthony BJ. Psychopharmacological and other treatments in preschool children with attention-deficit/hyperactivity disorder: current evidence and practice. J Child Adolesc Psychopharmacol. 2008;18:413-447.

73.  Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004;14:11-28.

74.  Garfield CF, Dorsey ER, Zhu S, et al. Trends in Attention Deficit Hyperactivity Disorder Ambulatory Diagnosis and Medical Treatment in the United States, 2000-2010. Acad Pediatr. 2012;12:110-116.

75.  Visser SN, Bitsko RH, Danielson ML, et al. Treatment of attention deficit/hyperactivity disorder among children with special health care needs. J Pediatr. 2015;166:1423-1430.

76.  Punja S, Shamseer L, Hartling L, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2016;(2):CD009996.

77.  Storebø OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015;(11):CD009885.

78.  MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999:56:1073-1086.

79.  MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit hyperactivity disorder. Pediatrics. 2004;113:754-761.

80.  Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007;46:989-1002.

81.  Brams M, Moon E, Pucci M, et al. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. Curr Med Res Opin. 2010;26:1809-1825.

82.  Faraone SV, Glatt SJ, Bukstein OG, et al. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord. 2009;12:308-315.

83.  Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19:353-364.

84.  Arnold LE. Methylphenidate vs. amphetamine: a comparative review. J Atten Disord. 2000;3:200-211.

85.  Chen Q, Sjölander A, Runeson B, et al. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ. 2014;348:g3769.

86.  Man KK, Coghill D, Chan EW, et al. Association of risk of suicide attempts with methylphenidate treatment. JAMA Psychiatry. 2017 Jul 26 [Epub ahead of print].

87.  Cheng JY, Chen RY, Ko JS, et al. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents: meta-analysis and meta-regression analysis. Psychopharmacology (Berl). 2007;194:197-209.

88.  Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41:776-784.

89.  Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with ADHD: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:E83.

90.  Buitelaar J, Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry. 2007;61:694-699.

91.  Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63:1140-1147.

92.  Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry. 2007;41:222-230.

93.  Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165:721-730.

94.  Scott NG, Ripperger-Suhler J, Rajab MH, et al. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2010;20:197-203.

95.  Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorder. Neurology. 2005;65:1941-1949.

96.  Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:1119-1127.

97.  US Food and Drug Administration. Public health advisory: suicidal thinking in children and adolescents being treated with Strattera (atomoxetine). September 2005. http://www.fda.gov/ (last accessed 7 August 2017).

98.  US Food and Drug Administration. Strattera (atomoxetine). September 2005. http://www.fda.gov/ (last accessed 7 August 2017).

99.  Banaschewski T, Roessner V, Dittman RW, et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry. 2004;13(suppl 1):I102-I116.

100.  Rains A, Scahill L, Hamrin V. Nonstimulant medications for the treatment of ADHD. J Child Adolesc Psychiatr Nurs. 2006;19:44-47.

101.  Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999;38:1551-1559.

102.  Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158:1067-1074.

103.  Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121:e73-e84.

104.  Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51:74-85.

105.  Sallee F, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:155-165.

106.  Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24:755-768.

107.  Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127:e1406-e1413.

108.  Croxtall JD. Clonidine extended-release: in attention-deficit hyperactivity disorder. Paediatr Drugs. 2011;13:329-336.

109.  Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996;35;1314-1321.

110.  Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005;57:793-801.

111.  Biederman J, Spencer T. Non-stimulant treatments for ADHD. Eur Child Adolesc Psychiatry. 2000;9(suppl 1):I51-I59.

112.  Biederman J, Baldessarini RJ, Wright V, et al. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. efficacy. J Am Acad Child Adolesc Psychiatry. 1989;28:777-784.

113.  Findling RL, Short EJ, Leskovec T, et al. Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008;18:347-354.

114.  Langberg JM, Arnold LE, Flowers AM, et al. Parent-reported homework problems in the MTA study: evidence for sustained improvement with behavioral treatment. J Clin Child Adolesc Psychol. 2010;39:220-233.

115.  Jones K, Daley D, Hutchings J, et al. Efficacy of the Incredible Years Programme as an early intervention for children with conduct problems and ADHD: long-term follow-up. Child Care Health Dev. 2008;34:380-390.

116.  Chan E, Fogler JM, Hammerness PG. Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. JAMA. 2016;315:1997-2008.

117.  Asarnow JR, Rozenman M, Wiblin J, et al. Integrated medical-behavioral care compared with usual primary care for child and adolescent behavioral health: a meta-analysis. JAMA Pediatr. 2015;169:929-937.

118.  Karpouzis F, Bonello R, Pollard H. Chiropractic care for paediatric and adolescent attention-deficit/hyperactivity disorder: a systematic review. Chiropr Osteopat. 2010;18:13.

119.  Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1284-1293. [Erratum in: Am Acad Child Adolesc Psychiatry. 2007;46:141.]

120.  American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108:1033-1044.

121.  Wilens T, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults who divert or misuse their prescribed medication. J Am Acad Child Adolesc Psychiatry. 2006;45:408-414.

122.  Sumner C, Sher L, Sutton V, et al. Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety - congress abstract. Neuropediatrics. 2006;37:TP74.

123.  Otasowie J, Castells X, Ehimare UP, et al. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2014;(9):CD006997.

124.  Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58:527-536.

125.  Biederman J, Pliszka SR. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. J Pediatr. 2008;152:394-399.

126.  Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: I. an 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990;29:546-557.

127.  Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of ADHD and related disorders. Arch Gen Psychiatry. 1996;53:437-446.

128.  Barkley RA. Driving impairment in teens and adults with ADHD. Psychiatr Clin North Am. 2004;27:233-260.

129.  Barkley RA, Fischer M, Smallish L, et al. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry. 2004;45:195-211.

130.  Barkley RA, Fischer M, Smallish L, et al. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adoles Pscyhiatry. 2006;45:192-202.

131.  Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol. 2004;14:65-73.

132.  Kidwell KM, Van Dyk TR, Lundahl A, et al. Stimulant medications and sleep for youth with ADHD: a meta-analysis. Pediatrics. 2015;136:1144-1153.

133.  Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child. 2005;90:801-806.

134.  Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46:1015-1027.

135.  Spencer TJ, Biederman J, Harding M, et al. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry. 1996;35:1460-1469.

136.  Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354:1445-1448.

137.  Hammerness PG, Perrin JM, Shelley-Abrahamson R, et al. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry. 2011;50:978-990.

138.  Villalaba L. Follow up review of AERS search identifying cases of sudden death occurring with drugs used for the treatment of attention deficit hyperactivity disorder (ADHD). 2006. http://www.fda.gov/ (last accessed 7 August 2017).

139.  Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896-1904.

140.  Shin JY, Roughead EE, Park BJ, et al. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ. 2016;353:i2550.

141.  Wilens TE, Spencer TJ, Swanson JM, et al. Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry. 1999;38:614-619.

142.  Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, placebo-controlled, parallel-group study of SL1381 (Adderall XR) in children with attention-deficit hyperactivity disorder. Pediatrics. 2002;110:258-266.

143.  Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit hyperactivity disorder. Pediatrics. 2001;108:883-892.

144.  Gadow KD, Sverd J, Sprafkin J, et al. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry. 1999;56:330-336.

145.  Gadow KD, Sverd J. Stimulants for ADHD in child patients with Tourette's syndrome: the issue of relative risk. J Dev Behav Pediatr. 1990;11:269-271.

146.  Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111:179-185.

147.  Wilens TE, Morrison NR. The intersection of attention-deficit/hyperactivity disorder and substance abuse. Curr Opin Psychiatry. 2011;24:280-285.

148.  Winhusen TM, Lewis DF, Riggs PD, et al. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21:455-463.

149.  Schoenfelder EN, Faraone SV, Kollins SH. Stimulant treatment of ADHD and cigarette smoking: a meta-analysis. Pediatrics. 2014;133:1070-1080.

150.  Vitiello B, Elliott GR, Swanson JM, et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry. 2012;169:167-177.

151.  Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117:2407-2423.

使用此内容应接受我们的免责声明。